Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00527033
Other study ID # 178-CL-045
Secondary ID
Status Completed
Phase Phase 2
First received September 6, 2007
Last updated February 14, 2017
Start date September 2007
Est. completion date April 2008

Study information

Verified date February 2017
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Examine which dose of YM178 is the best in terms of efficacy, safety and tolerability compared to placebo


Description:

To investigate the dose-response relationship of YM178 in terms of efficacy, safety and tolerability, and also the superiority of YM178 over placebo.


Recruitment information / eligibility

Status Completed
Enrollment 842
Est. completion date April 2008
Est. primary completion date April 2008
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- Patients over 20 years suffering from overactive bladder

Exclusion Criteria:

- Pregnant and breastfeeding women

- Any clinically significant abnormal conditions which in the opinion of the investigator makes the patient unsuitable for the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
YM178
Oral
Placebo
Oral

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Astellas Pharma Inc

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overactive bladder symptoms 12 weeks
Secondary Overactive bladder symptoms (QOL) 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06201013 - Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children N/A
Recruiting NCT05880862 - Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls Early Phase 1
Recruiting NCT04807920 - BOTOX® at the Time of Prolapse Surgery for OAB Phase 4
Terminated NCT02385500 - Fesoterodine on Urgency Episodes in Parkinson's Disease Population Phase 4
Not yet recruiting NCT02477241 - Brain Areas Involved in Bladder Filling and Contraction N/A
Completed NCT01698138 - Prevention of Bladder Dysfunction in Acute Spinal Cord Injury Phase 4
Completed NCT00613327 - An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants Phase 4
Completed NCT00368706 - A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients Phase 3
Recruiting NCT04305743 - Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A Phase 4
Active, not recruiting NCT03681678 - Laser Therapy for Treatment of Urogenital Symptoms in Women
Completed NCT01655069 - A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 Phase 3
Completed NCT01558856 - Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder N/A
Completed NCT01521767 - Pharmacokinetics and Relative Bioavailability Study Phase 1
Completed NCT01194999 - Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence Phase 4
Completed NCT01381120 - Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms Phase 4
Completed NCT01157377 - Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence Phase 2
Completed NCT01262391 - Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents Phase 1
Completed NCT04528784 - Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis N/A
Completed NCT02849418 - Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity Phase 3
Recruiting NCT05968885 - Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity Phase 4